11月6日 - 4D Molecular Therapeutics Inc宣布,来自1/2期PRISM临床试验的积极长期数据支持4D-150作为核心治疗的潜力,其在多年的治疗中展现出一致和持久的疗效。4D Molecular Therapeutics Inc表示,4D-150的耐受性良好,未出现新的安全问题。
11月6日 - 4D Molecular Therapeutics Inc宣布,来自1/2期PRISM临床试验的积极长期数据支持4D-150作为核心治疗的潜力,其在多年的治疗中展现出一致和持久的疗效。4D Molecular Therapeutics Inc表示,4D-150的耐受性良好,未出现新的安全问题。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.